{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T12:46:50Z","timestamp":1793710010783,"version":"4.6.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1007\/s00280-010-1473-z","type":"journal-article","created":{"date-parts":[[2010,9,30]],"date-time":"2010-09-30T07:42:06Z","timestamp":1285832526000},"page":"193-205","source":"Crossref","is-referenced-by-count":10,"title":["Preclinical toxicity and toxicokinetics of GTI-2040, a phosphorothioate oligonucleotide targeting ribonucleotide reductase R2"],"prefix":"10.1007","volume":"68","author":[{"given":"Eckhardt S.","family":"Ferdinandi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aikaterini","family":"Vassilakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"Lightfoot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitri","family":"Fitsialos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim A.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiping H.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,10,1]]},"reference":[{"key":"1473_CR1","doi-asserted-by":"crossref","first-page":"7066","DOI":"10.1016\/S0021-9258(19)50537-3","volume":"267","author":"RA Hurta","year":"1992","unstructured":"Hurta RA, Wright JA (1992) Alterations in the activity and regulation of mammalian ribonucleotide reductase by chlorambucil, a DNA damaging agent. J Biol Chem 267:7066\u20137071","journal-title":"J Biol Chem"},{"key":"1473_CR2","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1126\/science.8511586","volume":"260","author":"P Reichard","year":"1993","unstructured":"Reichard P (1993) From RNA to DNA, why so many ribonucleotide reductases? Science 260:1773\u20131777","journal-title":"Science"},{"key":"1473_CR3","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/jcp.1040940306","volume":"94","author":"WH Lewis","year":"1978","unstructured":"Lewis WH, Kuzik BA, Wright JA (1978) Assay of ribonucleotide reduction in nucleotide-permeable hamster cells. J Cell Physiol 94:287\u2013298","journal-title":"J Cell Physiol"},{"key":"1473_CR4","doi-asserted-by":"crossref","first-page":"14036","DOI":"10.1073\/pnas.93.24.14036","volume":"93","author":"H Fan","year":"1996","unstructured":"Fan H, Villegas C, Wright JA (1996) Ribonucleotide reductase R2 component is a novel malignancy determinant that cooperates with activated oncogenes to determine transformation and malignant potential. Proc Natl Acad Sci USA 93:14036\u201314040","journal-title":"Proc Natl Acad Sci USA"},{"key":"1473_CR5","first-page":"2802","volume":"63","author":"Y Lee","year":"2003","unstructured":"Lee Y, Vassilakos A, Feng N, Lam V, Xie H, Wang M, Jin H, Xiong K, Liu C, Wright J, Young A (2003) GTI-2040, an antisense agent targeting the small subunit component (R2) of human ribonucleotide reductase, shows potent antitumor activity against a variety of tumors. Cancer Res 63:2802\u20132811","journal-title":"Cancer Res"},{"key":"1473_CR6","first-page":"383","volume":"12","author":"RS Geary","year":"1997","unstructured":"Geary RS, Leeds JM, Henry SP, Monteith DK, Levin AA (1997) Antisense oligonucleotide inhibitors for the treatment of cancer: 1. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides. Anticancer Drug Des 12:383\u2013393","journal-title":"Anticancer Drug Des"},{"key":"1473_CR7","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1089\/oli.1.1997.7.575","volume":"7","author":"S Agrawal","year":"1997","unstructured":"Agrawal S, Zhao Q, Jiang Z, Oliver C, Giles H, Heath J, Serota D (1997) Toxicologic effects of an oligodeoxynucleotide phosphorothioate and its analogs following intravenous administration in rats. Antisense Nucleic Acid Drug Dev 7:575\u2013584","journal-title":"Antisense Nucleic Acid Drug Dev"},{"key":"1473_CR8","first-page":"395","volume":"12","author":"SP Henry","year":"1997","unstructured":"Henry SP, Monteith D, Levin AA (1997) Antisense oligonucleotide inhibitors for the treatment of cancer: 2. Toxicological properties of phosphorothioate oligodeoxynucleotides. Anticancer Drug Des 12:395\u2013408","journal-title":"Anticancer Drug Des"},{"key":"1473_CR9","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1177\/019262339902700117","volume":"27","author":"SP Henry","year":"1999","unstructured":"Henry SP, Templin MV, Gillett N, Rojko J, Levin AA (1999) Correlation of toxicity and pharmacokinetic properties of a phosphorothioate oligonucleotide designed to inhibit ICAM-1. Toxicol Pathol 27:95\u2013100","journal-title":"Toxicol Pathol"},{"key":"1473_CR10","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1177\/019262339902700103","volume":"27","author":"DK Monteith","year":"1999","unstructured":"Monteith DK, Levin AA (1999) Synthetic oligonucleotides: the development of antisense therapeutics. Toxicol Pathol 27:8\u201313","journal-title":"Toxicol Pathol"},{"key":"1473_CR11","doi-asserted-by":"crossref","first-page":"409","DOI":"10.2174\/156800906777723949","volume":"6","author":"J Shao","year":"2006","unstructured":"Shao J, Zhou B, Chu B, Yen Y (2006) Ribonucleotide reductase inhibitors and future drug design. Curr Cancer Drug Targets 6:409\u2013431","journal-title":"Curr Cancer Drug Targets"},{"key":"1473_CR12","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1093\/annonc\/mdi178","volume":"16","author":"AA Desai","year":"2005","unstructured":"Desai AA, Schilsky RL, Young A, Janisch L, Stadler WM, Vogelzang NJ, Cadden S, Wright JA, Ratain MJ (2005) A phase I study of antisense oligonucleotide GTI-2040 given by continuous intravenous infusion in patients with advanced solid tumors. Ann Oncol 16:958\u2013965","journal-title":"Ann Oncol"},{"key":"1473_CR13","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s00280-007-0524-6","volume":"61","author":"WM Stadler","year":"2008","unstructured":"Stadler WM, Desai AA, Quinn DI, Bukowski R, Poiesz B, Kardinal CG, Lewis N, Makalinao A, Murray P, Torti FM (2008) A Phase I\/II study of GTI-2040 and capecitabine in patients with renal cell carcinoma. Cancer Chemother Pharmacol 61:689\u2013694","journal-title":"Cancer Chemother Pharmacol"},{"key":"1473_CR14","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1158\/1078-0432.CCR-08-0109","volume":"14","author":"RB Klisovic","year":"2008","unstructured":"Klisovic RB, Blum W, Wei X, Liu S, Liu Z, Xie Z, Vukosavljevic T, Kefauver C, Huynh L, Pang J, Zwiebel JA, Devine S, Byrd JC, Grever MR, Chan K, Marcucci G (2008) Phase I study of GTI-2040, an antisense to ribonucleotide reductase, in combination with high-dose cytarabine in patients with acute myeloid leukemia. Clin Cancer Res 14:3889\u20133895","journal-title":"Clin Cancer Res"},{"key":"1473_CR15","first-page":"1","volume":"12","author":"SP Henry","year":"1997","unstructured":"Henry SP, Zuckerman JE, Rojko J, Hall WC, Harman RJ, Kitchen D, Crooke ST (1997) Toxicological properties of several novel oligonucleotide analogs in mice. Anticancer Drug Des 12:1\u201314","journal-title":"Anticancer Drug Des"},{"key":"1473_CR16","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/S0264-410X(00)00249-8","volume":"19","author":"AM Krieg","year":"2000","unstructured":"Krieg AM (2000) Immune effects and mechanisms of action of CpG motifs. Vaccine 19:618\u2013622","journal-title":"Vaccine"},{"key":"1473_CR17","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1146\/annurev.immunol.20.100301.064842","volume":"20","author":"AM Krieg","year":"2002","unstructured":"Krieg AM (2002) CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 20:709\u2013760","journal-title":"Annu Rev Immunol"},{"key":"1473_CR18","first-page":"421","volume":"12","author":"DK Monteith","year":"1997","unstructured":"Monteith DK, Henry SP, Howard RB, Flournoy S, Levin AA, Bennett CF, Crooke ST (1997) Immune stimulation\u2014a class effect of phosphorothioate oligodeoxynucleotides in rodents. Anticancer Drug Des 12:421\u2013432","journal-title":"Anticancer Drug Des"},{"key":"1473_CR19","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.4049\/jimmunol.164.3.1617","volume":"164","author":"G Hartmann","year":"2000","unstructured":"Hartmann G, Weeratna RD, Ballas ZK, Payette P, Blackwell S, Suparto I, Rasmussen WL, Waldschmidt M, Sajuthi D, Purcell RH, Davis HL, Krieg AM (2000) Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. J Immunol 164:1617\u20131624","journal-title":"J Immunol"},{"key":"1473_CR20","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1089\/oli.1.1997.7.503","volume":"7","author":"SP Henry","year":"1997","unstructured":"Henry SP, Novotny W, Leeds J, Auletta C, Kornbrust DJ (1997) Inhibition of coagulation by a phosphorothioate oligonucleotide. Antisense Nucleic Acid Drug Dev 7:503\u2013510","journal-title":"Antisense Nucleic Acid Drug Dev"},{"key":"1473_CR21","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1089\/ard.1993.3.309","volume":"3","author":"KW McIntyre","year":"1993","unstructured":"McIntyre KW, Lombard-Gillooly K, Perez JR, Kunsch C, Sarmiento UM, Larigan JD, Landreth KT, Narayanan R (1993) A sense phosphorothioate oligonucleotide directed to the initiation codon of transcription factor NF-kappa B p65 causes sequence-specific immune stimulation. Antisense Res Dev 3:309\u2013322","journal-title":"Antisense Res Dev"},{"key":"1473_CR22","doi-asserted-by":"crossref","first-page":"20372043","DOI":"10.1016\/0006-2952(93)90014-N","volume":"45","author":"RF Branda","year":"1993","unstructured":"Branda RF, Moore AL, Mathews L, McCormack JJ, Zon G (1993) Immune stimulation by an antisense oligomer complementary to the rev gene of HIV-1. Biochem Pharmacol 45:20372043","journal-title":"Biochem Pharmacol"},{"key":"1473_CR23","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/0378-4274(95)03571-0","volume":"82\u201383","author":"G Zon","year":"1995","unstructured":"Zon G (1995) Antisense phosphorothioate oligodeoxynucleotides: introductory concepts and possible molecular mechanisms of toxicity. Toxicol Lett 82\u201383:419\u2013424","journal-title":"Toxicol Lett"},{"key":"1473_CR24","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/S0022-3565(24)36667-4","volume":"281","author":"SP Henry","year":"1997","unstructured":"Henry SP, Giclas PC, Leeds J, Pangburn M, Auletta C, Levin AA, Kornbrust DJ (1997) Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: potential mechanism of action. J Pharmacol Exp Ther 281:810\u2013816","journal-title":"J Pharmacol Exp Ther"},{"key":"1473_CR25","first-page":"365","volume":"46","author":"DK Monteith","year":"1998","unstructured":"Monteith DK, Geary RS, Leeds JM, Johnston J, Monia BP, Levin AA (1998) Preclinical evaluation of the effects of a novel antisense compound targeting C-raf kinase in mice and monkeys. Toxicol Sci 46:365\u2013375","journal-title":"Toxicol Sci"},{"key":"1473_CR26","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0300-483X(97)03661-5","volume":"120","author":"SP Henry","year":"1997","unstructured":"Henry SP, Bolte H, Auletta C, Kornbrust DJ (1997) Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a four-week study in cynomolgus monkeys. Toxicology 120:145\u2013155","journal-title":"Toxicology"},{"key":"1473_CR27","first-page":"409","volume":"12","author":"SP Henry","year":"1997","unstructured":"Henry SP, Monteith D, Bennett F, Levin AA (1997) Toxicological and pharmacokinetic properties of chemically modified antisense oligonucleotide inhibitors of PKC-alpha and C-raf kinase. Anticancer Drug Des 12:409\u2013420","journal-title":"Anticancer Drug Des"},{"key":"1473_CR28","first-page":"379","volume":"77","author":"M Butler","year":"1997","unstructured":"Butler M, Stecker K, Bennett CF (1997) Cellular distribution of phosphorothioate oligodeoxynucleotides in normal rodent tissues. Lab Invest 77:379\u2013388","journal-title":"Lab Invest"},{"key":"1473_CR29","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1177\/019262339902700306","volume":"27","author":"DK Monteith","year":"1999","unstructured":"Monteith DK, Horner MJ, Gillett NA, Butler M, Geary R, Burckin T, Ushiro-Watanabe T, Levin AA (1999) Evaluation of the renal effects of an antisense phosphorothioate oligodeoxynucleotide in monkeys. Toxicol Pathol 27:307\u2013317","journal-title":"Toxicol Pathol"},{"key":"1473_CR30","first-page":"183","volume-title":"Antisense drug technology: principles, strategies and applications","author":"AA Levin","year":"2008","unstructured":"Levin AA, Yu RZ, Geary RS (2008) Basic principles of the pharmacokinetics of antisense oligonucleotide drugs. In: Crooke ST (ed) Antisense drug technology: principles, strategies and applications, 2nd edn. Taylor and Francis Group, Florida, pp 183\u2013215","edition":"2"},{"key":"1473_CR31","doi-asserted-by":"crossref","first-page":"E743","DOI":"10.1208\/aapsj080484","volume":"8","author":"X Wei","year":"2006","unstructured":"Wei X, Dai G, Liu Z, Cheng H, Xie Z, Marcucci G, Chan KK (2006) Metabolism of GTI-2040, a phosphorothioate oligonucleotide antisense, using ion-pair reversed phase high performance liquid chromatography (HPLC) coupled with electrospray ion-trap mass spectrometry. AAPS J 8:E743\u2013E755","journal-title":"AAPS J"},{"key":"1473_CR32","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0163-7258(97)00108-3","volume":"76","author":"S Agrawal","year":"1997","unstructured":"Agrawal S, Iyer RP (1997) Perspectives in antisense therapeutics. Pharmacol Ther 76:151\u2013160","journal-title":"Pharmacol Ther"},{"key":"1473_CR33","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/1520-6017(200102)90:2<182::AID-JPS9>3.0.CO;2-F","volume":"90","author":"RZ Yu","year":"2001","unstructured":"Yu RZ, Geary RS, Leeds JM, Watanabe T, Moore M, Fitchett J, Matson J, Burckin T, Templin MV, Levin AA (2001) Comparison of pharmacokinetics and tissue disposition of an antisense phosphorothioate oligonucleotide targeting human Ha-ras mRNA in mouse and monkey. J Pharm Sci 90:182\u2013193","journal-title":"J Pharm Sci"},{"key":"1473_CR34","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/0006-2952(95)00010-W","volume":"49","author":"R Zhang","year":"1995","unstructured":"Zhang R, Diasio RB, Lu Z, Liu T, Jiang Z, Galbraith WM, Agrawal S (1995) Pharmacokinetics and tissue distribution in rats of an oligodeoxynucleotide phosphorothioate (GEM 91) developed as a therapeutic agent for human immunodeficiency virus type-1. Biochem Pharmacol 49:929\u2013939","journal-title":"Biochem Pharmacol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-010-1473-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-010-1473-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-010-1473-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T04:09:12Z","timestamp":1740542952000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-010-1473-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10,1]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["1473"],"URL":"https:\/\/doi.org\/10.1007\/s00280-010-1473-z","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,10,1]]}}}